RE: Praluent (Alirocumab)-Induced Renal Injury.
作者信息
Rosenson Robert S, Larrey Dominique, Waters David D, Olsson Anders G
机构信息
1 Icahn School of Medicine at Mount Sinai, New York, NY, USA.
2 Hepato-Gastroentérologie, CHU de Montpellier, Hôpital Saint-Eloi, Montpellier, France.
出版信息
J Pharm Pract. 2018 Apr;31(2):138-139. doi: 10.1177/0897190017734429. Epub 2017 Oct 3.
Abstract
摘要
相似文献
1
RE: Praluent (Alirocumab)-Induced Renal Injury.关于：普来鲁肽（阿利西尤单抗）所致肾损伤。
J Pharm Pract. 2018 Apr;31(2):138-139. doi: 10.1177/0897190017734429. Epub 2017 Oct 3.
2
Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial.在心血管高危患者中，与添加依折麦布或将瑞舒伐他汀剂量加倍相比，添加阿利西尤单抗至瑞舒伐他汀的疗效和安全性：ODYSSEY OPTIONS II随机试验
Atherosclerosis. 2016 Jan;244:138-46. doi: 10.1016/j.atherosclerosis.2015.11.010. Epub 2015 Nov 14.
3
PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: alirocumab.前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂及其在高危患者中降低低密度脂蛋白胆固醇（LDL-C）水平的作用：阿利西尤单抗
Future Cardiol. 2016 Mar;12(2):149-57. doi: 10.2217/fca.15.88. Epub 2016 Feb 25.
4
Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease.阿利西尤单抗降低慢性肾脏病患者血脂的疗效和安全性。
Kidney Int. 2018 Jun;93(6):1397-1408. doi: 10.1016/j.kint.2017.12.011. Epub 2018 Mar 8.
5
Alirocumab (Praluent) to lower LDL-Cholesterol.阿利西尤单抗（波立达）用于降低低密度脂蛋白胆固醇。
Med Lett Drugs Ther. 2015 Aug 17;57(1475):113-5.
6
Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial.阿利西尤单抗联合阿托伐他汀与其他降脂治疗策略的比较：ODYSSEY OPTIONS I随机试验
J Clin Endocrinol Metab. 2015 Aug;100(8):3140-8. doi: 10.1210/jc.2015-1520. Epub 2015 Jun 1.
7
Praluent (Alirocumab)-Induced Renal Injury.
J Pharm Pract. 2017 Feb;30(1):7-8. doi: 10.1177/0897190016683304. Epub 2016 Dec 14.
8
[PCSK9 inhibition as the new hope for patients with familial hypercholesterolemia, statin intolerance and eventually for those at the highest cardiovascular risk? Focused on alirocumab, Praluent®].[前蛋白转化酶枯草溶菌素9（PCSK9）抑制：家族性高胆固醇血症、他汀类药物不耐受患者以及最终心血管风险最高的患者的新希望？聚焦于阿利西尤单抗（Praluent®）]
Vnitr Lek. 2015 Nov;61(11):946-51.
9
Successful treatment of a patient with statin-induced myopathy and myotonic dystrophy type II with proprotein convertase subtilisin/kexin type 9 inhibitor, alirocumab (Praluent).成功治疗了一名他汀类药物诱导的肌病和肌强直性肌营养不良 II 型患者，使用前蛋白转化酶枯草溶菌素/克酶素 9 抑制剂，阿利罗单抗（瑞百安）。
J Clin Lipidol. 2017 Nov-Dec;11(6):1485-1487. doi: 10.1016/j.jacl.2017.08.014. Epub 2017 Sep 4.
10
Alirocumab for the treatment of hypercholesterolaemia.依洛尤单抗治疗高胆固醇血症。
Expert Rev Clin Pharmacol. 2017 Jun;10(6):571-582. doi: 10.1080/17512433.2017.1318063. Epub 2017 Apr 18.
本文引用的文献
1
Praluent (Alirocumab)-Induced Renal Injury.
J Pharm Pract. 2017 Feb;30(1):7-8. doi: 10.1177/0897190016683304. Epub 2016 Dec 14.
2
Renal Tubular Toxicity Associated With Rosuvastatin Therapy.与罗苏伐他汀治疗相关的肾小管毒性。
Am J Kidney Dis. 2017 Mar;69(3):473-476. doi: 10.1053/j.ajkd.2016.08.037. Epub 2016 Nov 14.
3
Acute interstitial nephritis due to statin and its class effect.他汀类药物所致急性间质性肾炎及其类效应
Indian J Nephrol. 2015 Jan-Feb;25(1):54-6. doi: 10.4103/0971-4065.136883.
4
Rosuvastatin-induced acute interstitial nephritis.瑞舒伐他汀诱导的急性间质性肾炎。
Case Rep Nephrol Urol. 2013 Jun 13;3(1):87-90. doi: 10.1159/000353175. eCollection 2013.
5
Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases.使用强效他汀类药物与急性肾损伤入院率：行政数据库的多中心回顾性观察性分析。
BMJ. 2013 Mar 18;346:f880. doi: 10.1136/bmj.f880.
6
Accuracy and reproducibility of two scales in causality assessment of unexpected hepatotoxicity.两种量表在评估意外肝毒性因果关系中的准确性和可重复性。
J Clin Pharm Ther. 2012 Apr;37(2):196-203. doi: 10.1111/j.1365-2710.2011.01282.x. Epub 2011 Jul 1.
7
Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury.用于药物性肝损伤因果关系评估的Naranjo药物不良反应概率量表评价
Aliment Pharmacol Ther. 2008 May;27(9):780-9. doi: 10.1111/j.1365-2036.2008.03655.x. Epub 2008 Feb 18.
Zotero 插件